-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Dry eye disease (DED) is a common eye disease in ophthalmology clinics, often manifesting as eye fatigue, foreign body sensation, dryness and other symptoms
.
In 2020, there will be about 219 million dry eye patients in China, and the incidence of dry eye disease in China is increasing year by year
.
The huge patient population is in desperate need of new therapeutic drugs to better control dry eye, thus also giving rise to the growth of the dry eye drug market
.
Some data predict that the market size of dry eye drugs will increase significantly to more than 42.
6 billion yuan in 2030 at a compound growth rate of 30.
25%
.
In this context, many pharmaceutical companies are entering this field
.
Hengrui: SHR8028 Eye Drops Approved for Clinical On March 28, Hengrui Medicine announced that its subsidiary Shengdi Medicine has received the approval from the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" on SHR8028 Eye Drops.
, and clinical trials will be carried out in the near future
.
SHR8028 eye drops is a drug introduced by the company from Novaliq for the treatment of dry eye
.
It is understood that SHR8028 eye drops is a cyclosporine A preparation.
At present, in China, in addition to Hengrui, cyclosporine A eye drops for the treatment of dry eye syndrome are deployed, as well as Xingqi eye drops.
Class 3 generic drug cyclosporine eye drops (II), and this product has been approved by the State Food and Drug Administration in June 2020
.
3 pharmaceutical companies have applied for sodium hyaluronate eye drops Since March, Shanghai Haohai Biological/Beijing Huinland Pharmaceutical, Furou Medicine/Zhejiang Thermo Pharmaceutical and Shijiazhuang Green Pharmaceutical have all applied for sodium hyaluronate eye drops
.
Sodium hyaluronate eye drops is a drug for the treatment of dry eye syndrome, which is widely used in China
.
Data shows that in 2020, the sales of this product in the hospital have exceeded 800 million
.
In the first three quarters of 2021, the sales of this product in hospitals across the country are approaching 9 billion, and it is expected to become another billion-dollar drug product
.
However, in terms of market share, Germany's Wuzfam Pharmaceuticals has a relatively high proportion, followed by Santian Pharmaceuticals.
The products of these two pharmaceutical companies will account for over 80% of the market share in the hospital in 2020
.
The rest of the market is shared by Zhuhai Union, Qilu Pharmaceutical, and Zhejiang Jianfeng Pharmaceutical
.
At present, there are more than 20 companies that have applied for listing under the new registration classification in China.
Among them, 5 companies including Chengdu Push Pharmaceutical (the first reviewer), Jiangxi Zhenshiming Pharmaceutical, Zhongshan Wanhan Pharmaceutical, Yangzijiang and Zhongshan Wanyuan have passed the comment
.
Zhaoke Ophthalmology: Cyclosporine A Eye Gel plans to submit NDA in 2022 Recently, Zhaoke Ophthalmology disclosed the progress of the company's key pipelines
.
Among them, the blockbuster ophthalmic product cyclosporine A eye gel has completed a large-scale clinical trial in China, involving 644 patients in 41 centers
.
According to Zhaoke Ophthalmology's plan, the company will submit a New Drug Application (NDA) to the State Food and Drug Administration in the short term in 2022.
At the same time, it plans to submit a pre-NDA filing to the US FDA to conduct clinical research on cyclosporine A eye gel in the US Pave the way
.
Zhaoke Eye expects the product to achieve its commercialization target in 2023
.
Dimensional Bio: VVN001 Achieves Positive Results in U.
S.
Phase II Clinical Trial for Dry Eye On March 23, Dimensional Bio announced that its self-developed innovative drug VVN001 achieved positive results in U.
S.
Phase II clinical trial for dry eye
.
According to reports, this randomized, double-blind, vehicle-controlled phase II clinical trial aims to evaluate the safety and efficacy of VVN001 in patients with moderate to severe dry eye
.
The test results show that VVN001 can significantly improve the symptoms and signs of dry eye in patients, which will strongly support the upcoming Phase III clinical study of VVN001
.
VVN001 is a new and potent second-generation LFA-1 inhibitor independently developed by Vivo
.
In China, a Phase I clinical trial pharmacokinetic study of the product in Chinese healthy volunteers has also been completed, and a Phase II clinical trial in Chinese patients is underway
.
Based on the clinical trial results in the United States, VVN001 (5%) will conduct a pivotal Phase III clinical trial in China and the United States
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In 2020, there will be about 219 million dry eye patients in China, and the incidence of dry eye disease in China is increasing year by year
.
The huge patient population is in desperate need of new therapeutic drugs to better control dry eye, thus also giving rise to the growth of the dry eye drug market
.
Some data predict that the market size of dry eye drugs will increase significantly to more than 42.
6 billion yuan in 2030 at a compound growth rate of 30.
25%
.
In this context, many pharmaceutical companies are entering this field
.
Hengrui: SHR8028 Eye Drops Approved for Clinical On March 28, Hengrui Medicine announced that its subsidiary Shengdi Medicine has received the approval from the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" on SHR8028 Eye Drops.
, and clinical trials will be carried out in the near future
.
SHR8028 eye drops is a drug introduced by the company from Novaliq for the treatment of dry eye
.
It is understood that SHR8028 eye drops is a cyclosporine A preparation.
At present, in China, in addition to Hengrui, cyclosporine A eye drops for the treatment of dry eye syndrome are deployed, as well as Xingqi eye drops.
Class 3 generic drug cyclosporine eye drops (II), and this product has been approved by the State Food and Drug Administration in June 2020
.
3 pharmaceutical companies have applied for sodium hyaluronate eye drops Since March, Shanghai Haohai Biological/Beijing Huinland Pharmaceutical, Furou Medicine/Zhejiang Thermo Pharmaceutical and Shijiazhuang Green Pharmaceutical have all applied for sodium hyaluronate eye drops
.
Sodium hyaluronate eye drops is a drug for the treatment of dry eye syndrome, which is widely used in China
.
Data shows that in 2020, the sales of this product in the hospital have exceeded 800 million
.
In the first three quarters of 2021, the sales of this product in hospitals across the country are approaching 9 billion, and it is expected to become another billion-dollar drug product
.
However, in terms of market share, Germany's Wuzfam Pharmaceuticals has a relatively high proportion, followed by Santian Pharmaceuticals.
The products of these two pharmaceutical companies will account for over 80% of the market share in the hospital in 2020
.
The rest of the market is shared by Zhuhai Union, Qilu Pharmaceutical, and Zhejiang Jianfeng Pharmaceutical
.
At present, there are more than 20 companies that have applied for listing under the new registration classification in China.
Among them, 5 companies including Chengdu Push Pharmaceutical (the first reviewer), Jiangxi Zhenshiming Pharmaceutical, Zhongshan Wanhan Pharmaceutical, Yangzijiang and Zhongshan Wanyuan have passed the comment
.
Zhaoke Ophthalmology: Cyclosporine A Eye Gel plans to submit NDA in 2022 Recently, Zhaoke Ophthalmology disclosed the progress of the company's key pipelines
.
Among them, the blockbuster ophthalmic product cyclosporine A eye gel has completed a large-scale clinical trial in China, involving 644 patients in 41 centers
.
According to Zhaoke Ophthalmology's plan, the company will submit a New Drug Application (NDA) to the State Food and Drug Administration in the short term in 2022.
At the same time, it plans to submit a pre-NDA filing to the US FDA to conduct clinical research on cyclosporine A eye gel in the US Pave the way
.
Zhaoke Eye expects the product to achieve its commercialization target in 2023
.
Dimensional Bio: VVN001 Achieves Positive Results in U.
S.
Phase II Clinical Trial for Dry Eye On March 23, Dimensional Bio announced that its self-developed innovative drug VVN001 achieved positive results in U.
S.
Phase II clinical trial for dry eye
.
According to reports, this randomized, double-blind, vehicle-controlled phase II clinical trial aims to evaluate the safety and efficacy of VVN001 in patients with moderate to severe dry eye
.
The test results show that VVN001 can significantly improve the symptoms and signs of dry eye in patients, which will strongly support the upcoming Phase III clinical study of VVN001
.
VVN001 is a new and potent second-generation LFA-1 inhibitor independently developed by Vivo
.
In China, a Phase I clinical trial pharmacokinetic study of the product in Chinese healthy volunteers has also been completed, and a Phase II clinical trial in Chinese patients is underway
.
Based on the clinical trial results in the United States, VVN001 (5%) will conduct a pivotal Phase III clinical trial in China and the United States
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
